Investigation of morphological characteristics, membrance potential and membance patency in Escherichia coli following ciprofloxacin exposure

Abstract

Abstract: AIM: To study the changes of bacterial ultrastructure, membrance potential and membrance patency of Escherichia coli during the postantibiotic effect after exposure to gatifloxacin and ciprofloxacin in order to investigate the mechanisms of PAE.METHODS: During the Postantibiotic effect after exposure to gatifloxacin and ciprofloxacin, the aliquots were taken from the bacterial culture at regular intervals.Then the fluorescence microscope was used to observe changes in bacterial ultrastructure and at the same time we studied the changes of membrance potential and membrance patency in Escherichia coli during the postantibiotic effect by flow cytometry in conjunction with fluorescent probes.RESULTS: The PAE phase characterized by filament formation after exposure to gatifloxacin by fluorescence microscopy, yet no significant changes in membrance potential and membrance patency of Escherichia coli were observed.CONCLUSION: Gatifloxacin and ciprofloxacin can induce filamentation, and this change is indifferent with membrance potential and membrance patency of Escherichia coli.

Key words: gatifloxacin, ciprofloxacin, Postantibiotic effect, Escherichia coli

CLC Number:

R978.1

ZHU Man, WANG Rui, ZHANG Yong-qing, LIANG Bei-bei. Investigation of morphological characteristics, membrance potential and membance patency in Escherichia coli following ciprofloxacin exposure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(9): 1005-1009.

References

1 方翼, 王睿, 刘皈阳, 刘庆锋, 陈迁, 周亮, 等.3 种氟喹诺酮类药物抗生素后效应的研究[J].中国抗生素杂志,1997;22:67-70
2 Paster A, Peman J, Canton E.In vitro postanibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis[J].J Antimicrob Chemother, 1994; 34:679
3 Jepras RI, Paul FE, Perason SC, WilkinsonMJ.Rapid assessment of antibiotic effects on escherichia coli by bis-(1, 3-Dibutylbarbituric acid) trimethine oxonol and flow cytometry [J].Antimicrobial Agents Chemother, 1997;41:2001-5
4 Novo DJ, Perlmutter NG, Hunt RH, Shaprio HM.Multiparameter flow cytometric analy sis of antibiotic effects on membrane potential, membrance permeability, and bacterial counts of staphy lococcus aureus and micrococcus luteus[J].Antimicrobial Agents Chemotherapy, 2000;44:827-34
5 Dougherty TJ, Saukkonen JJ.Membrane permeability changes associated with DNA gyrase inhibitors in Escherichia coli[J]. Antimicrobial Agents Chemotherapy, 1985;28:200-6
6 雷军, 王浴生, 黎世能.诺氟沙星对大肠杆菌2280 的扫描电镜观察[J].中国抗生素杂志, 1994;19:66-7
7 Elliott TSJ, Sheltion A, Greenwood D.The response of Escherichia coli to ciprofloxacin and norfloxacin[J].JMedMicrobiol, 1987;23:83-8
8 Diver JM, Wise R.Morphological and biochemical changes in Escherichia coli after exposure to ciprofloxacin[J].J Antimicrobial Chemotherapy, 1986;18:31-41
9 Piddock LJY, Walters RN.Bactercidal activities of five quinolones for escherichia coli strains with mutations in genes encoding the SOS response or cell division[J].Antimicrobial Agents Chemotherapy, 1992;36:819-25
10 Piddock LJY, Walters RN, Diver JM.Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in Escherichia coli[J].Antimicrobial Agents Chemotherapy, 1990;34:2331-6
11 Lewin CS, Howard BMA, Ratcliffe NT, et alSimth TT..4-Quinolones and the SOS response[J].J Med Microbiol, 1989; 29:139-144
12 Wicken HJ, Pinney RJ, Mason DJ, Gant VA.Flow cytomeric investigation of filamentation, membrane patency, and membrane potential in escherichia coli following ciprofloxacin exposure[J].Antimicrobial Agents Chemotherapy, 2000;44:682-7

[1]	DENG Li, TIAN Jing. Resveratrol suppresses NLRP3 inflammasome activation in colonic epithelial cells triggered by Escherichia coli O104∶H4 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 167-173.
[2]	LI Pan, ZHAO Yi-bo, LI Xiao-li, LI Bin, ZHOU Hong. The sensitivity of LPS tolerance mice to Escherichia coli is mediated through modulation of pro-inflammatory cytokine release [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 261-265.
[3]	XIE Gang, AN Chang-Yong, ZHANG Cai-quan, TANG Hua. Impact of the Escherichia coli resistant line after colorectal cancer patients with preoperative oval intestinal antibiotics for bowel preparation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 433-437.
[4]	YU Meng-chen, PAN Xi-chun, LI Xiao-li, LI Jun, XIAO Kang-kang, LI Bin, ZHOU Hong. Artesunate enhance the ability of peritoneal macrophages endocytosing LPS and Escherichia coli and its mechnisms [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(1): 40-46.
[5]	ZHANG Rong, LI Bin, ZHANG Le-zhi, LI Jun, DING Guo-fu, HE Sheng-qi, LUO Ping, ZHOU Hong. Protective effects of Artesunate on mice challenged with heat-killed Escherichia coli [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 156-158.
[6]	LIU Wei, ZHOU Hong, DING Guo-fu, LU Yong-ling, WANG Liang-xi, LUO Ping. Protective effects of CpG oligonucleotide on mice with bacterial sepsis and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(3): 314-317.
[7]	ZHANG Jing, YU Ji-Cheng, CAO Guo-Yin, SHI Yao-Guo, WU Ju-Fang, CHEN Zhang-Jin, ZHANG Yin-Yuan. Clinical pharmacokinetics and bioequivalence of domestic gatifloxacin in Chinese male volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(5): 577-580.
[8]	ZHANG Yong-Qing, WANG Rui, ZHU Man, ZHANG Jian-Peng, ZHANG Yong-Mei, TONG Jun. Observation of morphology in Escherichia coli with atom microscope during the cefmetazole-induced post-antibiotic effect period [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(10): 1123-1127.
[9]	FANG Yi, WANG Rui, PEI Fei, CHAI Dong, ZHU Man, LIANG Bei-Bei, WANG Xi-Ping. Tolerability of gatifloxacin mehanesulfanae orally for 10 days in Chinese health volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(1): 70-73.
[10]	CHAI Dong, WANG Rui,PEI Fei, FANG Yi, ZHUMan, WANG Zhong-Xiao. Combined effects of clarithromycin and gatifloxacin on experimentalPneumonia withPseudomonas aeruginosa in rats as a model for biofilm-associated infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(6): 618-620.
[11]	WANG Ying. Comparison of efficacy and safety between gatifloxacin andlevofloxacin in treatment ofPatients withlight to moderate acutelower respiratory tract infections [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(4): 434-437.
[12]	ZHAO Huai-Jun, WANG Hui, FENG Jian-Qing, HUANG Jin-Shui. Effect of l-menthol on mucosa absorption of ciprofloxacin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(4): 314-316.
[13]	JIA Zhi-Fan, WANG Wei-Li, WONG Fu-Hai. Effect of ciprofloxacin on pharmacokinetics and pharmacodynamics of glipizide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2000, 5(3): 238-240.
[14]	WANG Rui, FANG Yi, CHEN Qian, LIU Gui-Yang, LIU Qing-Feng, LIU You-Ning. Study on the postantibiotic effects of twenty ant imicrobial agents against S.aureus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1999, 4(2): 146-149.
[15]	CHEN Qiang, WANG Rui, FANG Yi. Microbiological turbidimetric method in determination of serum concentrations of ciprofloxaxin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1998, 3(3): 190-191.